GENDER-SPECIFIC EFFECTS OF PHYSIOLOGIC GH ADMINISTRATION ON CARDIOVASCULAR RISK

生理性 GH 给药对心血管风险的性别特异性影响

• 批准号: 7607104
• 负责人: ANNE KLIBANSKI
• 金额: $ 0.71万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607104
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Gender; Grant; Heart Rate; Institution; Lipids; Physiological; Research; Research Personnel; Resources; Risk Marker; Source; United States National Institutes of Health; Woman; cardiovascular risk factor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will establish the gender-specific effect of physiologic GH replacement on cardiovascular risk in women with acquired GH deficiency by investigating whether this therapy: 1. has gender-specific effects on cardiovascular risk markers; 2. has gender-specific effects on lipid profiles; 3. alters heart rate variability and arterial distensibility in parallel with changes in cardiovascular risk markers; and 4. has different effects depending upon gonadal status.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究将通过调查生理性GH替代疗法是否： 1. 对心血管风险标志物具有性别特异性影响; 2. 对血脂有性别特异性影响; 3. 改变心率变异性和动脉扩张性，与心血管风险标志物的变化平行; 4. 根据性腺的状态有不同的影响。